Please assess the completion status of the following clinical trial:

Trial Title: Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≤ 80 years of age.~* Patient with diagnosis of COVID-19 infection with laboratory confirmation by reverse-transcription PCR (RT-PCR) of SARS-CoV-2 \<72 hours prior to study entry.~* Onset of symptoms \< 10 days prior to administration of study treatment.~* No more than 72 hours (3 days) of hospitalization before study treatment administration.~* Phase I criteria: Patients requiring hospitalization for COVID-19, with pneumonia diagnosed with chest radiograph or computed tomography imaging or lymphopenia (absolute lymphocyte counts below 1.2 x 109cells /L) AND O2Sat ≤ 94% on room air at screening, no oxygen requirement or with an oxygen need of ≤ 2.5 lpm in nasal cannula.~* Phase II criteria: Patients requiring hospitalization with pneumonia diagnosed with chest radiograph or computed tomography imaging or lymphopenia (absolute lymphocyte counts below 1.2 x 109cells /L) AND O2Sat ≤ 94% on room air at screening, requiring or not oxygen supplementation (nasal cannula, oxygen mask with reservoir, non-invasive ventilation, etc), but excluding mechanical ventilation.~* Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).~* Be willing and able to comply with study procedures.~* Patients with the ability to comprehend and sign the informed consent~* Written informed consent obtained prior to any screening procedures.~Exclusion Criteria:~* Enrolled in another Clinical Trial for COVID19.~* Rapidly progressive disease with anticipated life-expectancy \<72 hours.~* Patients requiring mechanical ventilation.~* Patients with multiorgan failure.~* Mild-moderate (grade ≥ 3) organ impairment (liver, kidney, respiratory), according to criteria from the National Cancer Institute (NCI CTCAE version 5.0).~* Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.~* Have a known history of human immunodeficiency virus infection, Hepatitis B or Hepatitis C; testing is not required in the absence of prior documentation or known history.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~* Any other condition that, in the opinion if the Investigator, may interfere with the efficacy and/or safety evaluation of the trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: allogeneic T memory cells (Type: EXPERIMENTAL): patients will receive memory T cells
- Arm B: allogeneic NK cells (Type: EXPERIMENTAL): patients will receive NK cells

Based on this trial design, predict the completion outcome and termination type (if applicable).